ABL001 demonstrated more potent anti-angiogenic and anti-cancer effects in vitro and in vivo, as compared to the VEGF-targeting or the DLL4-targeting monoclonal antibodies alone, in various assay systems [23,24]. The gene discussed is DLL4; the disease is cancer.